

Tasanee Braithwaite

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3844355/publications.pdf>

Version: 2024-02-01

41
papers

20,199
citations

394390

19
h-index

315719

38
g-index

41
all docs

41
docs citations

41
times ranked

32366
citing authors

#	ARTICLE	IF	CITATIONS
1	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	13.7	7,061
2	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	13.7	6,376
3	Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2017, 5, e1221-e1234.	6.3	2,053
4	Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2017, 5, e888-e897.	6.3	1,443
5	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2129-2143.	13.7	1,013
6	The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. <i>The Lancet Global Health</i> , 2021, 9, e489-e551.	6.3	549
7	Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. <i>The Lancet Global Health</i> , 2021, 9, e130-e143.	6.3	500
8	UK health performance: findings of the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 381, 997-1020.	13.7	479
9	<p>The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice</p>. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 9-24.	1.2	86
10	Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. <i>The Cochrane Library</i> , 2014, 2014, CD007325.	2.8	83
11	Autoimmune Retinopathy. <i>Ophthalmologica</i> , 2012, 228, 131-142.	1.9	75
12	New Systematic Review Methodology for Visual Impairment and Blindness for the 2010 Global Burden of Disease Study. <i>Ophthalmic Epidemiology</i> , 2013, 20, 33-39.	1.7	64
13	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. <i>JAMA Neurology</i> , 2020, 77, 1514.	9.0	45
14	Diagnostic features of the autoimmune retinopathies. <i>Autoimmunity Reviews</i> , 2014, 13, 534-538.	5.8	44
15	Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> , 2020, 104, 616-622.	3.9	36
16	Prevalence and causes of vision loss in sub-Saharan Africa in 2015: magnitude, temporal trends and projections. <i>British Journal of Ophthalmology</i> , 2020, 104, 1658-1668.	3.9	32
17	Multiple deprivation, vision loss, and ophthalmic disease in adults: global perspectives. <i>Survey of Ophthalmology</i> , 2018, 63, 406-436.	4.0	30
18	Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Population-Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immune-Mediated Inflammatory Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1267-1276.	5.6	25

#	ARTICLE	IF	CITATIONS
19	Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. , 2010, , CD007325.		24
20	The economics of vision impairment and its leading causes: A systematic review. EClinicalMedicine, 2022, 46, 101354.	7.1	24
21	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 9-14.	1.9	22
22	Prevalence and causes of vision loss in Latin America and the Caribbean in 2015: magnitude, temporal trends and projections. British Journal of Ophthalmology, 2019, 103, 885-893.	3.9	16
23	Instrument-based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review. Ocular Immunology and Inflammation, 2020, 28, 898-907.	1.8	16
24	National Eye Survey of Trinidad and Tobago (NESTT): prevalence, causes and risk factors for presenting vision impairment in adults over 40 years. British Journal of Ophthalmology, 2020, 104, 74-80.	3.9	15
25	Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study. British Journal of Ophthalmology, 2023, 107, 980-986.	3.9	12
26	Estimating the global cost of vision impairment and its major causes: protocol for a systematic review. BMJ Open, 2020, 10, e036689.	1.9	11
27	Health system dynamics analysis of eyecare services in Trinidad and Tobago and progress towards Vision 2020 Goals. Health Policy and Planning, 2018, 33, 70-84.	2.7	10
28	Does blindness count? Disability weights for vision loss. Clinical and Experimental Ophthalmology, 2017, 45, 217-220.	2.6	9
29	Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19. Lancet Rheumatology, The, 2021, 3, e818.	3.9	9
30	Addressing ethical challenges in the Genetics Substudy of the National Eye Survey of Trinidad and Tobago (GSNESTT). Applied & Translational Genomics, 2016, 9, 6-14.	2.1	6
31	The National Eye Survey of Trinidad and Tobago (NESTT): Rationale, Objectives and Methodology. Ophthalmic Epidemiology, 2017, 24, 116-129.	1.7	6
32	Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives. Ophthalmology and Therapy, 2020, 9, 215-220.	2.3	6
33	Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema. Eye, 2019, 33, 1830-1832.	2.1	4
34	Impact of Vision Loss on Health-Related Quality of Life in Trinidad and Tobago. Ophthalmology, 2019, 126, 1055-1058.	5.2	4
35	Self-reported visual difficulties in Europe and related factors: a European population-based cross-sectional survey. Acta Ophthalmologica, 2020, 99, 559-568.	1.1	3
36	Implications of the artificial intelligence extensions to the guidelines for consolidated standards of reporting trials and for standard protocol item recommendations for interventional trials (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57		

#	ARTICLE	IF	CITATIONS
37	Development and application of the ocular immune-mediated inflammatory diseases ontology enhanced with synonyms from online patient support forum conversation. <i>Computers in Biology and Medicine</i> , 2021, 135, 104542.	7.0	2
38	Capturing the experiences of patients with inherited optic neuropathies: a systematic review of patient-reported outcome measures (PROMs) and qualitative studies. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, , 1.	1.9	2
39	Subacute bilateral vision loss resulting from dengue maculopathy. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013200542-bcr2013200542.	0.5	1
40	Preventing blindness for patients with optic disc swelling: improving care using transformative new technology. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A74.3-A74.	1.9	1
41	Chronic optic disc swelling overlooked in a diabetic patient with a devastating outcome. <i>BMJ Case Reports</i> , 2010, 2010, bcr0620091975-bcr0620091975.	0.5	0